Soft Tissue Sarcoma Articles

Cediranib Reduces Tumor Burden in Sarcoma
Cediranib was associated with significantly reduced tumor burden and superior progression-free survival compared with placebo in patients with alveolar soft part sarcoma.
 
Radiation Therapy, Chemotherapy, Targeted Therapy, and Possibly Immunotherapy in Localized Sarcoma
As clinicians have gained an improved understanding of the biology of soft-tissue sarcoma malignancies, the ability to better distinguish and identify subtypes has extended the hope of targeted treatment options.
Aldoxorubicin was associated with superior progression-free survival compared with standard chemotherapy regimens and may be a viable treatment alternative for some patients with relapsed or refractory soft tissue sarcomas, according to results from a phase III international study.
FDA Grants Orphan Drug Status to Tazemetostat for Soft Tissue Sarcoma
Epizyme announced today that the FDA has granted orphan drug designation to its EZH2-inhibitor tazemetostat for the treatment of adults with INI1-negative epithelioid sarcoma.
Nivolumab/Ipilimumab Combo Active in Sarcoma
Dual checkpoint inhibition with nivolumab (Opdivo) plus ipilimumab (Yervoy) induced an objective response rate of 16% in patients with heavily treated, unselected, metastatic sarcoma, according to findings from the phase II ALLIANCE A091401 trial.
Adjuvant Radiotherapy Improves Survival in Rare Sarcoma Subtype
Adjuvant radiotherapy was associated with improved survival for patients with non-retroperitoneal abdominal soft tissue sarcomas (NRA-STS), but the addition of chemotherapy did not confer a similar survival benefit.
Chemoradiation and Radiation Produced Similar Outcomes in Extremity Soft Tissue Sarcoma
Researchers at Istanbul University Institute of Oncology have concluded that patients with high-risk extremity soft tissue sarcoma have similar 3-year outcomes whether they are assigned to neoadjuvant sequential chemoradiotherapy or radiation alone.
Doxorubicin/Ifosfamide Combo for Sarcoma Most Effective in Select Population
Chemotherapy with doxorubicin and ifosfamide improved progression-free survival and tumor response compared with doxorubicin alone in soft tissue sarcoma, but the combination may be best suited for young, fit patients.
 
Apatinib Shows Potential in Advanced Sarcoma
Chinese researchers have concluded that the oral VEGFR2 inhibitor apatinib demonstrated efficacy with tolerable toxicity in a small study of patients with stage IV sarcoma, according to results published in Oncotarget.
Comprehensive Genomic Profiling Could Improve Diagnoses, Treatment in Sarcoma
Researchers at MD Anderson Cancer Center believe that including clinical genomic profiling into sarcoma management could result in more precise diagnosis and subclassification of the disease.
Publication Bottom Border
Border Publication